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Background: The herb formulation Deva-5 is used in traditional medicine to treat acute infectious diseases. Deva-5
is composed of five herbs: Gentiana decumbens L., Momordica cochinchinensis L., Hypecoum erectum L., Polygonum
bistorta L., and Terminalia chebula Retz. Deva-5 and its five components were investigated for in vitro antiviral
activity against avian influenza A virus subtype H3N8.
Methods: The water extracts of the herbal parts of G. decumbens, H. erectum and P. bistorta, the seeds of T. chebula
and M. cochinchinensis and Deva-5 were prepared by boiling and clarified by low-speed centrifugation and filtration.
To assess the antiviral properties, avian influenza virus isolate A/Teal/Tunka/7/2010(H3N8) was incubated at 37°C
for 30 min in the presence and absence of the extracts of five plants and DEVA-5 in various concentrations.
Subsequently, the concentration of infectious virus in each sample was determined by plaque assays. Neutralisation
indexes and 90% plaque reduction concentrations were estimated for each extract, and the significance of the data
was evaluated using statistical methods.
Results: The extracts of G. decumbens, H. erectum, P. bistorta and Deva-5 demonstrated no significant toxicity at
concentrations up to 2%, whereas extracts of T. chebula and M. cochinchinensis were well-tolerated by Madin-Darby
canine kidney cells at concentrations up to 1%. The extracts of H. erectum, M. cochinchinensis and T. chebula reduced
the titre of A/Teal/Tunka/7/2010 (H3N8) by approximately five-fold (p ≤ 0.05). The other three extracts did not
significantly reduce the infectivity of the virus. The plaque reduction neutralisation tests revealed that none of the
extracts tested were able to inhibit formation of plaques by 90%. However, three extracts, H. erectum, T. chebula and
M. cochinchinensis, were able to inhibit formation of plaques by more than 50% at low dilutions from 1:3 to 1:14.
The T. chebula extract had a concentration-dependent inhibitory effect.
Conclusions: For the first time, the consistent direct antiviral action of the extracts of H. erectum, T. chebula and M.
cochinchinensis was detected. These extracts significantly reduced the infectivity of influenza A virus H3N8 in vitro
when used at high concentrations (0.5–1%). However, Deva-5 itself and the remainder of its components did not
exhibit significant antiviral action. The results suggest that H. erectum, T. chebula and M. cochinchinensis plants
contain substances with direct antiviral activity and could be promising sources of new antiviral drugs.
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Influenza A virus (IAV) is important pathogen that causes
acute disease in humans and domestic animals. In
Mongolia, during the 2010/2011 influenza season, an
average of 1,232 influenza-like illnesses per 10,000 people
was recorded, comprising 5.8% of all recorded outpatient
visits [1].
The IAV belongs to the family Orthomyxoviridae and is
currently divided into subtypes according to the structure
of the major virion proteins – haemagglutinin (HA) and
neuraminidase (NA). To date, up to 17 subtypes of HA
and up to 10 subtypes of NA have been differentiated [2].
Birds are the natural host of the virus and can harbour
any subtype of IAV. However, from time to time, some
avian IAVs adapt to mammalian hosts, posing a serious
threat to healthcare and the economy [3]. For example,
the human-avian reassortant virus H3N2 entered the hu-
man population in 1968 and is currently the major agent
of seasonal flu, causing 3–5 million human cases of acute
respiratory illness worldwide [3,4]. Equine IAV (H3N8)
causes acute disease in horses and regularly diverges from
avian IAV, most recently occurring in 1989 [5]. At present,
equine IAV affects 2.1 million Mongolian horses and crit-
ically impacts the economy and nomadic livelihood in
Mongolia [6].
The herb formulation Deva-5 is used in traditional
medicine to treat acute infectious diseases [7]. Deva-5 is
composed of five different herbs: Gentiana decumbens
L. (26.3%), Momordica cochinchinensis L. (18.4%), Hype-
coum erectum L. (15.7%), Polygonum bistorta L. (23.6%)
and Terminalia chebula Retz. (15.7%) [8].
G. decumbens is traditionally used to cure infectious dis-
eases and stomach disorders [9]. It has been reported to
have potent anti-oxidant activity [10]. In traditional medi-
cine, M. cochinchinensis is used to treat liver, stomach and
kidney disorders, and it has detoxifying and antipyretic
properties [9]. The anti-inflammatory, anti-oxidant, and
antitumor activities of M. cochinchinensis have been dem-
onstrated [11-13]. H. erectum is used to cure infectious
disorders in traditional medicine, and it has antibacterial,
antinociceptive and antipyretic properties [9]. Studies have
shown antibacterial and anti-inflammatory activities of H.
erectum [14,15]. P. bistorta reduces oedema and is used to
treat lung disorders in traditional medicine [9]. Its anti-
inflammatory effect has been reported [16]. T. chebula has
been described in books of traditional medicine as a pana-
cea and is used for the treatment of most diseases, espe-
cially stomach disorders [9]. T. chebula has been most
extensively studied among the constituents of Deva-5. It
has a wide spectrum of pharmacological and medicinal ac-
tivities that include anti-oxidative, antibacterial, antiviral,
anti-inflammatory and immunomodulatory activities
[17,18]. Recently, it was shown to protect epithelial cells
against damage caused by influenza A virus [19].In the present study, we probed the direct antiviral ef-
fects of Deva-5 and its constituents against the recently
isolated avian influenza virus H3N8, which is homolo-
gous in its HA structure to human H3N2 and equine
H3N8 influenza viruses of epidemiological and veterin-
ary importance.
Methods
Plant material and preparation of extracts
The aerial parts of G. decumbens, H. erectum, and P. bis-
torta were obtained from Tuv province in Mongolia;
seeds of M. cochinchinensis and T. chebula were
imported from China. The Deva-5 herb formulation and
its five components were prepared in the traditional
medical factory of the Traditional Medical Science Tech-
nology and Production Corporation of Mongolia. The
plants were identified by a botanist at the Institute of
Traditional Medicine, and voucher specimens were de-
posited and are publicly available at the Herbarium of
Institute of Traditional Medicine, Mongolian National
University of Medical Sciences (abbreviation of the herb-
arium, tserentsoo@mnums.edu.mn).
To minimise the effect of the preparation procedures
on the bioactive compounds in the herbs, the extracts
were prepared with boiling water. Briefly, 30 g, 10 g, 2 g
or 1 g of each plant material was suspended in 200 ml of
sterile double distilled water (ddH2O) and boiled at low
heat for 15–30 min. When the total volume of the ex-
tract had reached a volume slightly less than 100 ml, the
extracts were measured and made up to 100 ml with
sterile ddH2O if necessary. Then, the extracts were fil-
tered through a sterile gauze filter and finally through
sterile 0.45 μm filter paper. All extraction and purifica-
tion work was done aseptically and the resulting extracts
were stored at +4°C for 1–2 h before the experiments.
Cells
Madin-Darby canine kidney (MDCK) cells were pur-
chased from BioloT (Saint Petersburg, Russian Feder-
ation). Cells were maintained at 37°C in DMEM culture
media (with L-glutamine) supplemented with 10% foetal
calf serum, 25 mМ HEPES and 0.2% bovine serum albu-
min. The cells were sub-cultured twice a week using
0.25% trypsin solution supplemented with 0.5 mM
EDTA (BioloT, Saint Petersburg, Russian Federation).
Virus maintenance and plaque titration assay
Avian influenza virus (AIV) isolate A/Teal/Tunka/7/
2010(H3N8) was obtained from cloacal swabs of Euro-
pean teal (Anas crecca) sampled in eastern Siberia in
2010. The virus underwent three passages in chicken
embryos and one passage in MDCK cells. The stock
virus was propagated in DMEM culture media supple-
mented with 25 mМ HEPES, 0.2% bovine serum
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aliquoted and stored at −80°C until use [20]. Infected
cell cultures were incubated at 37°C in humidified 5%
CO2. Plaque titrations were performed in quadruplicates
according to Gaush and Smith [21], with minor modifi-
cations. Briefly, the virus suspension was serially 10-fold
diluted using serum-free DMEM up to 10−8, and 250 μl
of each dilution was inoculated in corresponding wells
of a 24-well plate with 90% confluent MDCK cells. After
1 h of adsorption at room temperature, the inocula were
discarded, and the cells were washed with serum-free
DMEM and overlaid with DMEM supplemented with 25
mМ HEPES, 0.2% bovine serum albumin, 2 μg/ml of
TPCK-trypsin, antibiotics and 1% low melting point
agarose (Sigma). The plates were incubated at room
temperature until the overlay media became solid, and
then they were placed in a 5% CO2 humidified atmos-
phere at 37°C. On day 3 post infection, the monolayers
were fixed with a 10% solution of formalin in phosphate
buffered saline (PBS, pH 7.4) overnight and plaques were
visualised by staining with a 0.05% solution of crystal
violet in ddH2O. The plaques were counted, and virus
concentration was expressed as the number of plaque
forming units in one millilitre of suspension (PFU/ml).
RNA extraction, reverse transcription and PCR
The virus RNA was extracted from 100 μl of allantoic fluid
using a RiboPrep RNA extraction kit (Amplisens,
Moscow). The RNA pellet was dissolved in 50 μl of RNA
dilution buffer, and 10 μl of RNA solution was used to
synthesise the cDNA with random hexamers using the
Reverta-L kit (Amplisens, Moscow) according to the man-
ufacturer’s manual. The RT reaction mixture was incu-
bated at 37°C for 1 h, followed by 15 min at 70°C. The
effectiveness of cDNA synthesis was evaluated by a PCR
assay with the primers CU-MF 5` TGATCTTCTTGA
AAATTTGCAG 3` and CU-MR 5` TGTTGACAAAAT-
GACCATCG 3` to amplify a 276-bp fragment of the gene
for the matrix (M) protein with high sensitivity, as de-
scribed by Payungporn et al. [22]. The subtype of HA was
identified using an H1-H15-specific RT-PCR assay de-
signed by Tsukamoto et al. [23]. Briefly, 15 separate PCR
reactions were run with subtype-specific primer pairs. The
primers were synthesised commercially according to the
previously mentioned report [23]. Each PCR reaction was
performed in volume of 25 μl and contained 2.5 μl of
cDNA, 2.5 μl of PCR buffer (Sigma), 10 mM dNTP (New
England Biolabs), 10 pmol of each primer, 1.5 mM MgSO4
and 0.5 μl of DiaTaq DNA polymerase (Amplisens,
Moscow). The conditions of PCR included initial denatur-
ation at 94°C for 5 min followed by 35 cycles of denatur-
ation at 94°C for 30 sec, annealing at 50°C for 30 sec and
elongation at 72°C for 30 sec. Final elongation was per-
formed at 72°C for 5 min. The resulting PCR productswere resolved on a 2% agarose gel with ethidium bromide
staining.
Nucleotide sequencing and phylogenetic analysis
The isolate A/Teal/Tunka/7/2010 has not been previ-
ously identified by serological or genetic methods.
Therefore, we confirmed the HA subtype identification
and identified the NA subtype by phylogenetic analysis
of nucleotide sequences of the HA and NA genes in
comparison with reference sequences representing all
known subtypes of influenza A [24].
The fragments of genes coding for HA and NA were
amplified using the procedure developed by Hoffmann
et al. [25]. A detailed list of primers used in this study is
given in Table 1. The PCR reaction was performed in a
volume of 100 μl as described above. The PCR products
were resolved on a 0.8% agarose gel, excised from the
gel and purified with the QIAgen PCR purification kit
(Qiagen). The PCR products were directly sequenced
using Sanger’s dideoxy termination method, and ob-
tained nucleotide sequences were deposited in GenBank
with accession numbers KF790581 and KF790582 for
the HA and NA gene fragments, respectively. Sequences
were edited and aligned using BioEdit software.
The set of reference sequences included the GenBank
accession numbers AF091309 (H1), AY633196 (H2N3),
L11129 (H2N9), AY531037 (H3), D90302 (H4), U20460
(H5), AY968676 (H6), U20462 (H7), AB289343 (H8),
AY206671 (H9), CY087832 (H10), D90306 (H11),
AB288334 (H12), AF250362 (N1), AJ574904, DQ067439
(N2), AY207522, AY207524, AY207513 (N3), CY003986,
CY004180 (N4), EU429794 (N5), AY207549 (N6),
AB472061, CY014993 (N7), L06587 (N8) and AB292780
(N9). The phylogenetic analysis was performed with the
neighbour-joining method; the estimation of evolution-
ary distances was made based on the Tamura-Nei 93
model of evolution [26], and the significance of the ob-
tained models was evaluated by bootstrap analysis with
1000 replications. The clusters supported by a 70%
bootstrap value and higher were assumed to be signifi-
cant. The Mega 5 program package was used to perform
the phylogenetic analysis.
Evaluation of the toxicity of herb extracts in MDCK cells
MDCK cells were grown to confluence in 96-well cul-
ture plates (Sarstedt, USA) and treated in quadruplicate
with serial two-fold dilutions of herb extracts in main-
tenance media, i.e. from 15% to 0.03%. A series of two-
fold dilutions of PBS (pH 7.4) in maintenance media was
used as the control. Plates were incubated at 37°C in 5%
CO2 for 7 days. The morphology and viability of cells
was evaluated daily using light microscopy. By the seventh
day of incubation, cells were washed with sterile PBS
(pH 7.4) prewarmed to 37°C, fixed with 10% formalin and
Table 1 Primers used to amplify and sequence the fragments of HA and NA genes of A/Teal/Tunka/7/2010 (H3N8)
Title Sequence, 5′ - > 3′ Target gene References
H3-919 F gyatyactccwaatggaagc HA Tsukamoto et al. [23]
Bm-NS-890R atatcgtctcgtattagtagaaacaagggtgtttt HA Hoffmann et al. [25]
Bm-NA-1 L tattggtctcagggagcaaaagcaggagt NA Hoffmann et al. [25]
Bm-NA-1413R atatggtctcgtattagtagaaacaaggagtttttt NA Hoffmann et al. [25]
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monolayers were dried, and the stain was extracted with
100 μl of pure methanol. The number of surviving cells
was evaluated by measuring the optical density of the cor-
responding extract at a wavelength of 630 nm using an
Immunochem 2100 microplate spectrophotometer (High
Technology Inc., USA).
Virus neutralisation test
MDCK cells were grown to confluence in 24-well plates.
Replicates of AIV A/Teal/Tunka/7/2010 (H3N8) were
diluted in culture media without foetal calf serum to
achieve a virus concentration of approximately 1 × 105
PFU in 500 μl. Then, 500 μl of the virus suspension was
mixed with 500 μl of freshly prepared 2% extracts of G.
decumbens, H. erectum, P. bistorta, and Deva-5 or 1%
extracts of T. chebula and M. cochinchinensis. Specific
anti-HA antibodies to homologous H3 subtype of influ-
enza A virus were used as the positive control for neu-
tralisation. The antibodies were bought as a commercial
antiserum against influenza virus H3N2 (Research Insti-
tute of Influenza, Saint Petersburg, Russian Federation).
The antiserum was diluted 1:10 in sterile ddH2O, and
100 μl of diluted serum was mixed with 400 μl of main-
tenance media and 500 μl of the virus suspension. The
negative control was prepared by mixing 500 μl of sterile
ddH2O with 500 μl of the virus suspension. The mix-
tures were incubated at 37°C for 30 min, and then the
concentration of infectious virus in each sample was
established using plaque assays. The neutralisation index
was estimated as the quotient of the AIV concentration
in the negative control to the AIV concentration in the
test sample. This test was performed with six independ-
ent repeats.
Plaque reduction neutralisation test (PRNT)
The 2% extracts of G. decumbens, H. erectum, P. bistorta
and Deva-5 or 1% extracts of T. chebula and M.
cochinchinensis were serially diluted two-fold to a con-
centration of 0.016% in DMEM media supplemented
with 25 mМ HEPES, 0.2% bovine serum albumin, 2 μg/
ml of TPCK-trypsin and antibiotics. Sterile ddH2O and
the specific antihaemagglutin antibodies to the homolo-
gous H3 subtype of Influenza A virus were used as con-
trols as described above. Each dilution of the extracts
and controls was supplemented with approximately 200PFU of A/Teal/Tunka/7/2010 (H3N8) virus and incubated
at 37°C for 30 min. Afterwards, each sample was placed
into the wells of 12- or 24-well plates with a 90% confluent
monolayer of MDCK cells. Adsorption was conducted at
room temperature for 60 min, and then the inocula were
discarded and monolayers were covered with overlay media
for the plaque assay. At day 3 post infection, the cells were
fixed, and the plaques were visualised with crystal violet
and counted. Four independent repeats were done for
plaque reduction neutralisation test. The 50% and 90% in-
hibition doses were estimated for each extract as the max-
imal reciprocal dilution of extract that inhibited plaque
formation by 50% or 90% (ID50% and ID90%, respectively).
Data analysis
Results are presented as the mean value of at least four in-
dependent repeats. The standard deviation of the mean was
used to evaluate the variability of data. The Kolmogorov-
Smirnof test was used to check the normality of the sample,
and Student’s t-test was used to evaluate differences be-
tween samples. A value of p ≤ 0.05 was considered statisti-
cally significant. The ID50% and ID90% were estimated
using probit analysis. The relationship between the concen-
tration of extracts and infectivity of the treated virus was
evaluated using the Pearson correlation test. The correl-
ation was assumed to be significant at R > 0.7 (p = 0.05).
Data analysis was performed using Statistica 6.1 and MSOf-
fice EXCEL 2003 software.
Results
Virus subtype and culture properties
The isolate A/Teal/Tunka/7/2010 (H3N8) caused a clear
cytopathic effect in MDCK cells on day 3 post infection.
At this time, it produced small (0.3–0.5 mm) plaques and
reached a titre of 1 ± 0.2 × 106 PFU/ml. The subtype-
specific RT-PCR produced a single band with primers cor-
responding to the HA subtype H3. The phylogenetic ana-
lysis of the fragments of HA and NA genes had shown
that isolate A/Teal/Tunka/7/2010 (H3N8) has HA of the
H3 subtype and NA of the N8 subtype (Figure 1).
Plant extracts are toxic for MDCK cells at concentrations
higher than 2%
All plant extracts were toxic to MDCK cells at concen-
trations higher than 2%. The most toxic extracts were
derived from T. chebula and M. cochinchinensis, causing
AB
Figure 1 Identification of subtype of influenza A virus isolate
A/Teal/Tunka/7/2010. A – phylogenetic analysis of a 714 bp
fragment of the HA gene; B – phylogenetic analysis of a 1216 bp
fragment of the NA gene. The sequences of A/Teal/Tunka/7/2010
are labelled with inverted triangles. The phylogenetic analysis was
performed using the neighbour-joining method; the estimation of
evolutionary distances was made on the basis of the Tamura-Nei 93
model of evolution Tamura and Nei [26]. The significance of trees
was evaluated by bootstrap analysis with 1000 replications.
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0.06%. Plant extracts from P. bistorta and the Deva-5
composition were less toxic, as single MDCK cells were
detected under the light microscope when the culture
media contained up to 7.5% of those preparations, al-
though no cells survived at higher concentrations. The
results of the cell viability assay at concentrations of
plant extracts less than 2% are presented in Figure 2.
The cytotoxic effect was dose-dependent, and the
plant extracts had different cytotoxic profiles. Thus, the
highly toxic extracts of T. chebula and M. cochinchinen-
sis killed up to 100% of cells, except for the very low
concentrations of 0.5% and 0.13%, respectively. At higher
dilutions, these preparations caused a dose-dependent
increase in cell viability and became non-toxic at con-
centrations of 0.13% and 0.03%, respectively. The ex-
tracts of G. decumbens, P. bistorta and Deva-5 expressed
weak cytopathic effects and did not cause significant
damage to cells at concentrations of 2% and less. The
extracts of H. erectum destroyed 80% of cells at 2%, but
after being diluted only twice, they caused no significant
cytopathic effects. These results suggest that extracts of
G. decumbens, H. erectum, P. bistorta and Deva-5 have
no significant toxicity at concentrations of 2% and less,
whereas extracts of T. chebula and M. cochinchinensis
were well-tolerated by MDCK cells at concentrations
0.13% and 0.03%, respectively.
Virus neutralisation by plant extracts
Treatment of high doses of virus with high concentra-
tions of plant extracts did not affect the infectivity of
virus, with the exception of extracts of H. erectum, M.
cochinchinensis and T. chebula. These three extracts sig-
nificantly reduced the infectivity of A/Teal/Tunka/7/
2010 (H3N8) by approximately five-fold (Figure 3). The
specific antibodies reduced virus infectivity by 100-fold,
which indicates the weak neutralising ability of these
plant extracts.
The plaque reduction neutralisation tests revealed that
none of the extracts were able to inhibit plaque forma-
tion by 90%. However, three extracts, i.e. H. erectum, T.
chebula and M. cochinchinensis, inhibited plaque forma-
tion by more than 50% at low dilutions, i.e. from 1:3 to
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Figure 2 Viability of MDCK cells (%) treated with different
concentrations of plant extracts. The lowest concentration at
which toxic (or enhancing) effects reach statistical significance
(p < 0.05) are labelled by quadrangular stars.
Table 2 Direct antiviral action of plant extracts against
influenza A virus A/Teal/Tunka/7/2010 (H3N8)
Extract NI ± SD* ID50%**
Gentiana decumbens, 1% extract 1.4 ± 0.7 -
Hypecoum erectum, 1% extract 4.8 ± 0.2 8.6
Polygonum bistorta, 1% extract 1.6 ± 0.1 -
Terminalia chebula, 0.5% extract 4.9 ± 0.2 13.4
Momordica cochinchinensis, 0.5% extract 5.1 ± 0.3 2.7
DEVA-5, 1% extract 1.6 ± 0.4 -
H3N2 Abs, diluted as 1:100 93.9 ± 0.7 59.1
* - approximately 1 × 105 PFU of A/Teal/Tunka/7/2010 (H3N8) were used for
the NI assay.
** - approximately 200 PFU of A/Teal/Tunka/7/2010 (H3N8) were used for the
PRNT assay.
The neutralisation index (NI) was estimated as the quotient of the virus
concentration in the water-treated sample to the virus concentration in the
test sample. The 50% inhibition dose was estimated using probit analysis as
the maximal reciprocal dilution of extract that inhibited the formation of
plaques by 50%.
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dilution of 1:6 (ID90% = 6) and plaque formation by 50%
at a dilution of 1:60 (ID50% = 59.1). Only one prepar-
ation, T. chebula, exhibited a significant positive correl-
ation (R > 0.7 at p = 0.05) between the dilution factor of
the extract and the infectivity of the virus (Figure 4).
These results are summarised in Table 2 where the neu-
tralisation indexes and 50% inhibition doses are given.
Discussion
Deva-5 is used in traditional medicine to treat infectious
diseases, including seasonal and epidemic flu. G. decumbens
































































Figure 3 Titres of infectious virus in samples containing ~1 ×
105 PFU A/Teal/Tunka/7/2010 (H3N8) treated with 1% plant
extracts. Control – water-treated virus; H3N2 Abs - A/Teal/Tunka/7/
2010 (H3N8) treated with 1:100 diluted specific antibodies to the
H3N2 influenza virus. Green blocks designate the samples that
showed a significant reduction in viral titres in comparison to the
control by Student’s t-test (p ≤ 0.05). Error bars reflect
standard deviations.in books of traditional medicine [9]. In this study, we tested
the antiviral activities of the traditional drug Deva-5 and its
components against avian influenza virus H3N8 in cell cul-
ture. The virus strain A/Teal/Tunka/7/2010 (H3N8) used
in our study was previously characterised in a very re-
stricted set of experiments. Therefore, we sequenced the
HA and NA genes to exclude possible misidentification of
the virus subtype or the misplacement of virus stock. The
genetic identification of the virus subtype was performed
by phylogenetic analysis in comparison with reference
strains of each subtype and confirmed the virus identity.
Although Deva-5 did not show concentration-dependent
antiviral activity, some signs of virus inhibition by Deva-5
were observed at the 1% concentration of the extract
(Figure 4). This effect can be explained by the presence of
three components that consistently reduced the infectivity
of A/Teal/Tunka/7/2010 (H3N8): H. erectum and T. che-
bula and M. cochinchinensis. These three extracts inhibited
the virus much more weakly than specific anti-HA anti-
bodies; however, this may have been due to the very low
concentrations of bioactive substances in the water extracts.
For example, in similar research on Scutellaria baicalensis,
the authors used 30 g of a crude powder treated with
200 ml of various organic solvents. Afterwards, the prepara-
tions were freeze-dried, and working solutions with concen-
trations of extract equal to 1 mg/ml were prepared. Under
these conditions, the IC50 in PRNT against IAV H1N1 var-
ied from 14 μg/ml to 134 μg/ml [27]; this approximately
corresponds to a reciprocal dilution from 10 to 100. In our
research, we used only 1–2 grams of homogenised herbs or
seeds, and in the PRNT these extracts exhibited an IC50
equal to a reciprocal dilution between 8 and 14. So, it is
likely that, if the concentration of biologically active com-
ponents had been increased (e.g. by freeze-drying, or with
chemical fractionation to remove toxic substances), the
Figure 4 Neutralising activity of different concentrations of plant extracts against influenza A virus A/Teal/Tunka/7/2010 (H3N8). Red
line – specific antibodies to the H3 subtype of influenza A virus; green – non-treated virus; blue – virus treated with the corresponding plant
extract. The data reflect the mean values of four independent repeats of the PRNT assay as described in the Methods; error bars show standard
deviations. The correlation coefficients R between the reciprocal dilution of extracts and infectivity of A/Teal/Tunka/7/2010 (H3N8) are shown in
each panel. The correlation was assumed to be statistically significant at R > 0.7 (p = 0.05).
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well. Thus, although Deva-5 and its constituents have
extremely low antiviral activity, if any, the extracts of
H. erectum, T. chebula and M. cochinchinensis are
promising potential sources of new antiviral drugs.
Deva-5 exhibited weak cytotoxicity and did not cause
significant damage to MDCK cells at concentrations
less than 2%. The possible rationale for the use of
Deva-5 instead of separate plant extracts is the cumula-
tive effect of the action of its constituents. Indeed, the
extracts of H. erectum, T. chebula and M. cochinchinen-
sis exhibited antiviral action, but were also quite toxic
to mammalian cells (Figure 2). In contrast, the extracts
of G. decumbens and P. bistorta exhibited no antiviral
action, but possessed very low cytotoxicity. Moreover,
an approximate increase of 60% in the cell number in
samples treated with extracts of P. bistorta suggests
that this constituent may have a stimulating effect on
mammalian cell growth (Figure 2). Thus, Deva-5 con-
sists of two types of components: “antivirals” that exert
inhibition of the virus but also destroy mammaliancells; and “cell protectors” that compensate for the
negative effects of antiviral constituents.
It has been previously reported that the H. erectum plant
contains steroidal saponins, alkaloids, and coumarins [14].
However, no antiviral substances have been isolated from
this plant. Likewise, no reports have been published on
antiviral constituents isolated from M. cochinchinensis. This
plant was shown to contain momorchochin, alkenes, fatty
acids, carotenoids, triterpenoidal saponins, cochinin B and
a specific chymotripsin inhibitor. Three other plants have
been reported to contain phenolic compounds and flavo-
noids that possess strong anti-influenza viral activity [12].
In addition G. decumbens contains secoiridoids and alka-
loids, P. bistorta contains fatty acids, steroids and triterpe-
noids, and T. chebula contains fatty acids, fructose, amino
acids, anthraquinone and triterpenoids [17]. The protective
activity of T. chebula against influenza A virus (H1N1) has
been reported; however, in contrast to our findings, no dir-
ect antiviral activity of the water extract of T. chebula was
detected in this study [19]. This discrepancy may have been
caused by the different subtype of IAV used in our study
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might have a subtype-specific inhibitory activity against
IAV. Further research is necessary to resolve this question.
Thus, for the first time, the direct antiviral action of two
components of the Deva-5 herb formulation, H. erectum
and T. chebula, was demonstrated in this work.
Our preliminary study showed that Deva-5 inhibited the
growth of Staphylococcus aureus. Hexane and dichloro-
methane extracts from M. cochinchinensis leaves, as well
as seven alkaloids isolated from H. erectum, have anti-
microbial activity against a number of Gram-negative and
Gram-positive bacteria, including Staphylococcus aureus
[28,14]. Bag et al. showed that a hot aqueous extract of T.
chebula fruit was found to be potent against Staphylococ-
cus aureus strains, whereas an ethanol extract was found
to be more potent against Escherichia coli strains [18].
Also, an aqueous extract of T. chebula exhibited antifun-
gal activity against a number of dermatophytes and patho-
genic yeasts and the acetone extract of T. chebula seeds
showed antiplasmodial activity against Plasmodium falcip-
arum [18]. Taken together, these results suggest that ra-
tionality of the use of Deva-5 in traditional medicine to
treat infectious diseases can be explained by the antiviral
and antimicrobial properties of its components.
Conclusions
For the first time, the consistent direct antiviral action of
extracts of H. erectum, T. chebula and M. cochinchinen-
sis was demonstrated. These extracts significantly re-
duced the infectiveness of influenza A virus H3N8
in vitro when used at high concentrations (0.25–1%).
However, Deva-5 itself and the remainder of its compo-
nents did not exhibit significant antiviral activity. These
results suggest that the former three plants contain sub-
stances with significant antiviral activity and could be a
promising source of new antiviral drugs. However, further
research, including in vivo tests in an animal model, is ne-
cessary to identify the biologically active components and
to remove toxic substances.
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